Holen Sie sich die Stockscreener-App
1.95
9.30%
-0.20
Handel nachbörslich:
1.95
Schlusskurs vom Vortag:
$2.15
Offen:
$2
24-Stunden-Volumen:
29,771
Relative Volume:
1.34
Marktkapitalisierung:
$15.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-2.4176
EPS:
-0.8066
Netto-Cashflow:
-
1W Leistung:
-8.51%
1M Leistung:
-8.02%
6M Leistung:
-35.00%
1J Leistung:
-43.31%
1-Tages-Spanne:
$1.79
$2.17
1-Wochen-Bereich:
$1.79
$2.30
52-Wochen-Spanne:
$1.79
$3.78
Neuraxis Inc Stock (NRXS) Company Profile
Firmenname
Neuraxis Inc
Sektor
Branche
Telefon
(812) 689-0791
Adresse
11550 North Meridian Street, Suite 325, Carmel
Vergleichen Sie NRXS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NRXS
Neuraxis Inc
|
1.95 | 15.51M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Neuraxis Inc Aktie (NRXS) Neueste Nachrichten
Neuraxis stock hits 52-week low at $1.98 amid market challenges - Investing.com Australia
NeurAxis, Inc. (NASDAQ:NRXS) Q4 2024 Earnings Call Transcript - MSN
NeurAxis (NASDAQ:NRXS) Trading Down 0.9% – Should You Sell? - Defense World
NeurAxis Stock Gains Post Q4 Earnings And Revenue Growth - Barchart
NeurAxis Stock Gains Post Q4 Earnings and Revenue Growth - Zacks Investment Research
NeurAxis (NASDAQ:NRXS) & BioLife Solutions (NASDAQ:BLFS) Head-To-Head Analysis - Defense World
NeurAxis, Inc. Reports Strong Q4 Growth Amid Challenges - TipRanks
NeurAxis revenues increase 43% to USD 761K in Q4 2024 - Medical Buyer
NeurAxis, Inc. Reports Strong Q4 2024 Results - TipRanks
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows - Investing.com Canada
Earnings call transcript: Neuraxis Q4 2024 sees revenue growth, loss narrows By Investing.com - Investing.com South Africa
NeurAxis Better on Q4 Results - Baystreet.ca
NeurAxis, Inc. Reports 43% Revenue Growth in Q4 2024 and Significant Milestones Achieved - Nasdaq
NeurAxis Reports Strong Fourth Quarter 2024 Financial Results Driven by a 43% Increase in Revenues - GlobeNewswire
Earnings Scheduled For March 20, 2025 - Benzinga
NeurAxis, Inc. Set to Announce Fourth Quarter and Fiscal Year 2024 Financial Results on March 20, 2025 - Nasdaq
NeurAxis to Host Fourth Quarter and Full Year 2024 Results and Business Update Call on Thursday, March 20, 2025 - GlobeNewswire
NRXS stock touches 52-week low at $1.99 amid market challenges By Investing.com - Investing.com South Africa
NRXS stock touches 52-week low at $1.99 amid market challenges - Investing.com
Vagus Nerve Stimulators Market Detailed In New Research Report - openPR
NeurAxis (NASDAQ:NRXS) Stock Price Down 2.8% – Here’s Why - Defense World
Chronic Idiopathic Constipation Clinical Trials and Pipeline - openPR
Critical Contrast: NeurAxis (NASDAQ:NRXS) & Zynex (NASDAQ:ZYXI) - Defense World
Vagus Nerve Stimulators Market Witness Growth: Booming Demand, - openPR
Analyzing NeurAxis (NASDAQ:NRXS) and Masimo (NASDAQ:MASI) - Defense World
End Of January 2025 Portfolio Review - substack.com
FDA Clears NeurAxis’ Self-Inflating Balloon Device - MPO-mag
Financial Contrast: NeurAxis (NASDAQ:NRXS) versus ENDRA Life Sciences (NASDAQ:NDRA) - Defense World
NeurAxis, Inc. Announces New Medical Policy Coverage with a Prominent Insurer for over Five Million Lives Across Multiple States - Marketscreener.com
UPDATENeurAxis Announces New Medical Policy Coverage with a Prominent Insurer for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Expands IBS Treatment Coverage to 51M Lives, Targets Youth Market with Novel Device - StockTitan
NeurAxis Announces New Medical Policy Coverage with Molina Healthcare for Over Five Million Lives Across Multiple States - The Manila Times
NeurAxis Announces New Medical Policy Coverage with Molina - GlobeNewswire
NeurAxis Expands Coverage for FDA-Cleared IBS Pain Device to 51M Lives with Molina Deal - StockTitan
NeurAxis announces Q4 preliminary unaudited revenues were about $800 thousand - MSN
Vagus Nerve Stimulators Market Growth in Future Scope 2025-2032 - openPR
Critical Analysis: Precision Optics (NASDAQ:POCI) & NeurAxis (NASDAQ:NRXS) - Defense World
Vaso Corporation Announces Executive Leadership Appointments & Names New Vice Chairman to the Board of Directors - The Manila Times
NeurAxis Inc. Issues Letter to Shareholders - GlobeNewswire
NeurAxis IB-Stim Reaches Major Milestone: Insurance Coverage Surges to 51 Million Lives, FDA Expands Age Range - StockTitan
AAR Corporation (NYSE: AIR) Issues Press Release and Slide Presentation on Q2 2025 Financial Results - Defense World
Amplitude Healthcare Acquisition (OTCMKTS:AMHCU) Announces Positive Preliminary Data from Jasper Therapeutics, Inc. BEACON Phase 1b/2a StudyOn January 8, 2025, Jasper Therapeutics, Inc. released a press release detailing encouraging preliminar - Defense World
NeurAxis, Inc. Reports Strong Preliminary Unaudited Fourth Quarter 2024 Results - Defense World
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth Quarter 2024 Results; Revenues Increased 50% Year-Over-Year - Marketscreener.com
Everything Blockchain Inc. Announces Letter to Shareholders from CEO - The Manila Times
NeurAxis Inc. Announces Strong Preliminary Unaudited Fourth - GlobeNewswire
NeurAxis Q4 Revenue Surges 50% as IB-Stim Coverage Reaches 45 Million Lives - StockTitan
Finanzdaten der Neuraxis Inc-Aktie (NRXS)
Es liegen keine Finanzdaten für Neuraxis Inc (NRXS) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.23%
1.63%
Kapitalisierung:
|
Volumen (24h):